Direct Compression Behaviour and Granulation Thresholds for Bailong Powder in Veterinary Tablet Cores

In tablet manufacture, Bailong Powder is incorporated into oral veterinary tablet cores at 30–50% w/w for standardised dry extract and at 40–60% w/w when the raw botanical powder is used after pin milling to a particle size D90 ≤ 75 µm. The remaining core consists of microcrystalline cellulose 20–35% w/w, croscarmellose sodium 2–4% w/w, and magnesium stearate 0.5–1.0% w/w. The drug substance is released against the current national veterinary pharmacopoeia monograph for Bailong Powder where available, or the manufacturer’s technical dossier under the applicable veterinary medicinal product regulation, with heavy metals, total ash, and microbial enumeration included in release testing. Batch manufacture on a high-shear wet granulation line with an impeller speed of 300 rpm and chopper speed of 1,500 rpm is preferred, followed by fluidised-bed drying at inlet air temperature 60–70 °C and product temperature 40–50 °C to a final loss on drying of 3.5–5.0% w/w. On a 16-station D-tooling rotary press, precompression is set at 5 kN and main compression at 8–18 kN; tablet hardness is maintained at 60–100 N. When extract loading exceeds 50% w/w, lower-punch adhesion and edge lamination are observed on production-scale machines, particularly at ambient relative humidity above 60%; on 24-station rotary presses the maximum practical loading without excipient compaction aids is 50% w/w, above which turret speed must be reduced below 20 rpm and feed shoe paddle depth adjusted. Release testing follows Ph. Eur. 2.9.1, Ph. Eur. 2.9.3, and Ph. Eur. 2.9.5, with residual moisture, disintegration time below 15 min in water at 37 °C, and individual mass variation recorded in line under 21 CFR 211.110. Finished dosage forms include 100 mg, 200 mg, and 500 mg tablets for companion animals and young ruminants.

What Limits the Sterile Filtration Flux of Bailong Extract Solutions in Veterinary Parenteral Manufacture?

Injectable dosage production from Bailong Powder is restricted to a purified, deproteinised aqueous extract of the drug substance, not the raw botanical powder. The final extract solids content is controlled at 1.0–2.5% w/v, equivalent to 10–25 g crude Bailong Powder per litre before sterile filtration. The preparation is produced by decoction at 95–100 °C for 60 min, followed by ethanol precipitation at 60–70% v/v, refrigerated settling for 12 h, and ultrafiltration through a 10 kDa membrane to remove high-molecular-weight polysaccharides and proteinaceous material. The filtrate is passed through a 0.45 µm pre-filter and a terminal 0.22 µm PVDF sterilising-grade membrane at 20–30 L/m²/h; flux declines when the extract contains more than 0.5 mg/mL total protein or when the temperature falls below 18 °C. Filter integrity is verified before and after the campaign by the manufacturer’s specified bubble point test for the membrane lot. The filled ampoules or vials must meet Ph. Eur. 2.6.1 sterility and Ph. Eur. 2.6.14 bacterial endotoxin limits according to EU GMP Annex 1 within an ISO 14644-1:2015 Class 5 cleanroom. Because endotoxin load in crude herbal extracts may exceed 0.5 EU/mL, depyrogenation is validated to reduce it to below 0.25 EU/mL; if terminal sterilisation is performed at 121 °C for 15 min, the extract must withstand the thermal cycle without precipitation. In multi-dose presentations, benzyl alcohol 1.0–2.0% v/v is used as preservative only after confirming compatibility with the extract. Finished terminal products are 10 mL, 20 mL, and 50 mL intramuscular injection vials for cattle and swine under veterinary prescription.

Capsule filling of Bailong Powder for companion-animal dispensary markets uses a low-shear granulate, not direct powder fill, because the crude drug substance has a broad particle size distribution and poor flow through dosator nozzles. The bulk fill formulation contains Bailong Powder at 55–75% w/w, lactose monohydrate 15–30% w/w, crospovidone 2–4% w/w, colloidal silicon dioxide 0.5–1.0% w/w, and magnesium stearate 0.5–1.0% w/w. Granulation is performed in a top-spray fluid bed at product temperature 35–45 °C, yielding a granulate with pour density 0.50–0.65 g/mL and Carr index below 20%. A dosator-type capsule machine operating at 30,000–60,000 capsules/h fills 250 mg and 500 mg total fill weights with mass variation below ±5%; in-line checkweighing rejects capsules outside ±3% of mean fill weight at 10-min intervals. The shells are hard gelatin capsules with equilibrium moisture 13–15% w/w; storage above 60% RH causes shell softening and content clumping. Compliance is measured by Ph. Eur. 2.9.1 disintegration, Ph. Eur. 2.9.5 uniformity of mass, and USP <905> content uniformity; in-process checks follow 21 CFR 211.110. Terminal products are 250 mg and 500 mg veterinary oral capsules for dogs, cats, and managed zoo ungulates where individual animal dosing is required.

For production of water-dispersible oral powders, Bailong Powder is micronised by jet milling to a particle size D90 ≤ 75 µm and blended with lactose monohydrate 85–90% w/w, citric acid 0.2–0.5% w/w, and anhydrous sodium carbonate 0.1–0.3% w/w to maintain pH 5.0–6.0 on reconstitution. The Bailong Powder addition ratio in the finished oral powder is 10% w/w; this is diluted in drinking water at the farm to a suspension of 1–2 g powder per litre, corresponding to 0.1–0.2 g active ingredient per litre for poultry and 0.2–0.4 g active ingredient per litre for swine. Mixing is performed in a 200 kg V-blender at 12 rpm for 15–20 min; segregation of micronised Bailong Powder from coarse lactose is controlled by matching particle densities and keeping carrier moisture below 2.0% w/w. Filling is carried out at 25–30 °C and ≤40% RH to avoid lactose caking and moisture uptake by the botanical fraction; foil laminate sachets with moisture vapour transmission rate below 0.1 g/m²/day are required. The filled foil sachets are tested for mass uniformity under Ph. Eur. 2.9.5, powder fineness under USP <811>, and microbial limits according to the national veterinary pharmacopoeia. The main production failure in intensive poultry dosing is sedimentation and nipple drinker blockage when the powder is rehydrated, so the formulation is processed to ensure re-dispersibility; published data for this specific configuration is limited. Terminal products include 1 g, 5 g, 50 g, and 500 g foil sachets for oral administration to pigs, broilers, and layers.

When Bailong Powder Is Converted to Fluidised Bed Granules for Pre-Ruminant and Neonatal Livestock Dosing

Conversion of Bailong Powder into oral granules for pre-ruminant calves and lambs requires a binder-assisted wet granulation step because the finely divided botanical drug substance exhibits poor flow and high dusting. The granule formulation contains Bailong Powder at 45–65% w/w, mannitol or lactose monohydrate 25–45% w/w, povidone K30 1–2% w/w as binder, sodium starch glycolate 2–4% w/w, and sodium benzoate 0.05–0.1% w/w if the granules are intended for reconstitution. Top-spray fluidised bed processing uses inlet air temperature 65–75 °C, product temperature 35–45 °C, atomising air pressure 1.5–2.5 bar, and peristaltic spray rate 20–40 g/min; final loss on drying is controlled to 2.0–3.5% w/w. Dried granules are sieved to 500–1,000 µm; over-wetting during spraying produces agglomerates above 1,000 µm that fail to disintegrate within 15 min in water at 37 °C. Granule dissolution in milk replacer at 40 °C must occur within 10 min without floating residue; insoluble agglomerates above 1,000 µm are removed by a vibratory sieve before packing. Batch-to-batch variation on production-scale units is most sensitive to binder solution addition time and inlet dew point; sustained humidity above 10 g/m³ in the fluidising air causes premature granule coalescence. Compliance testing includes sieve analysis under USP <786>, powder flow under Ph. Eur. 2.9.36, uniformity of mass under Ph. Eur. 2.9.5, and loss on drying under Ph. Eur. 2.2.32. The terminal products are 1 g, 2 g, and 5 g oral granule sachets for piglets, calves, and lambs, designed for either direct oral administration or mixing into milk replacer.

Medicated Premix Dilution Geometry and Carryover Control in Feed Mills

Feed-mill premix production using Bailong Powder requires a geometrically staged dilution protocol because the active ingredient is added at low final dosage rates to large volumes of complete feed. Bailong Powder is first blended into a carrier premix at 5–10% w/w with calcium carbonate or wheat middlings, then diluted further at the feed mill so that complete feed contains 0.2–0.5% w/w Bailong Powder, equivalent to 2–5 kg per tonne of finished feed. The main equipment is a horizontal ribbon mixer of 1,000–2,000 kg batch capacity operated at 30 rpm for 10–15 min; active-marker coefficient of variation must remain below 5% after mixing and after discharge. In production-scale mills, electrostatic adhesion of the fine botanical powder to mixer walls and dust extraction filters creates a negative assay bias at the first dilution stage; this is corrected by increasing the first-stage premix loading to 10% w/w and by grounding the mixer housing. Carryover control follows 21 CFR Part 225 using a sequenced flush of 2% w/w salt or rice hulls after every medicated batch; equipment surfaces are inspected for residue accumulation under 21 CFR 225.10–225.65. The premix itself is packed in 25 kg multi-wall paper sacks with inner polyethylene liner and labelled under the requirements of Regulation (EU) 2019/4 for medicated feed intermediates. Terminal products are 1%, 5%, and 10% Bailong Powder premixes for licensed feed mills supplying swine, poultry, and ruminant production.

Aqueous oral solution dosage forms based on Bailong Powder require a clarified liquid extract rather than a simple suspension, because raw botanical particles block nipple drinker valves and compromise dose uniformity in intensive poultry houses. The finished oral solution contains Bailong extract solids at 2.0–4.0% w/v, preserved with sodium benzoate 0.1–0.2% w/v and potassium sorbate 0.05–0.1% w/v; pH is adjusted to 4.5–5.5 with citric acid or sodium hydroxide to maintain preservative activity and reduce phenolic oxidation. The production line uses a closed stainless-steel mixing tank at 1,000 rpm, followed by plate-and-frame clarification, 0.45 µm depth filtration, and terminal 0.22 µm membrane filtration; the filtered solution is filled into high-density polyethylene bottles under nitrogen or low-oxygen headspace. The closure system uses induction-sealed HDPE bottles with oxygen transmission rate below 0.5 cm³/container/day at 23 °C to limit oxidative browning. Turbidity is measured against Ph. Eur. 2.2.1, pH by Ph. Eur. 2.2.3, and microbial quality by Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13; preservative efficacy is evaluated by Ph. Eur. 5.1.3. Prolonged storage above 25 °C or light exposure above 5,000 lux increases colour shift and precipitation in the bottle, so amber HDPE containers are required. Terminal products are 500 mL, 1 L, and 5 L oral solutions for poultry, swine, and pre-ruminant administration through dosing pumps or direct oral drench.